260 related articles for article (PubMed ID: 31144428)
1. Use of fast-acting insulin aspart in insulin pump therapy in clinical practice.
Evans M; Ceriello A; Danne T; De Block C; DeVries JH; Lind M; Mathieu C; Nørgaard K; Renard E; Wilmot EG
Diabetes Obes Metab; 2019 Sep; 21(9):2039-2047. PubMed ID: 31144428
[TBL] [Abstract][Full Text] [Related]
2. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
Klonoff DC; Evans ML; Lane W; Kempe HP; Renard E; DeVries JH; Graungaard T; Hyseni A; Gondolf T; Battelino T
Diabetes Obes Metab; 2019 Apr; 21(4):961-967. PubMed ID: 30537180
[TBL] [Abstract][Full Text] [Related]
3. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial.
Heise T; Zijlstra E; Nosek L; Rikte T; Haahr H
Diabetes Obes Metab; 2017 Feb; 19(2):208-215. PubMed ID: 27709762
[TBL] [Abstract][Full Text] [Related]
5. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.
Buse JB; Carlson AL; Komatsu M; Mosenzon O; Rose L; Liang B; Buchholtz K; Horio H; Kadowaki T
Diabetes Obes Metab; 2018 Dec; 20(12):2885-2893. PubMed ID: 30259644
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
Mathieu C; Bode BW; Franek E; Philis-Tsimikas A; Rose L; Graungaard T; Birk Østerskov A; Russell-Jones D
Diabetes Obes Metab; 2018 May; 20(5):1148-1155. PubMed ID: 29316130
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
Bode BW; Iotova V; Kovarenko M; Laffel LM; Rao PV; Deenadayalan S; Ekelund M; Larsen SF; Danne T
Diabetes Care; 2019 Jul; 42(7):1255-1262. PubMed ID: 31076415
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9).
Lane WS; Favaro E; Rathor N; Jang HC; Kjærsgaard MIS; Oviedo A; Rose L; Senior P; Sesti G; Soto Gonzalez A; Franek E
Diabetes Care; 2020 Aug; 43(8):1710-1716. PubMed ID: 32209647
[TBL] [Abstract][Full Text] [Related]
9. Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences.
Haahr H; Heise T
Clin Pharmacokinet; 2020 Feb; 59(2):155-172. PubMed ID: 31667789
[TBL] [Abstract][Full Text] [Related]
10. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
Russell-Jones D; Bode BW; De Block C; Franek E; Heller SR; Mathieu C; Philis-Tsimikas A; Rose L; Woo VC; Østerskov AB; Graungaard T; Bergenstal RM
Diabetes Care; 2017 Jul; 40(7):943-950. PubMed ID: 28356319
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus.
Haahr H; Pieber TR; Mathieu C; Gondolf T; Shiramoto M; Erichsen L; Heise T
Clin Pharmacokinet; 2019 May; 58(5):639-649. PubMed ID: 30402720
[TBL] [Abstract][Full Text] [Related]
12. Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes.
Zijlstra E; Demissie M; Graungaard T; Heise T; Nosek L; Bode B
J Diabetes Sci Technol; 2018 Jan; 12(1):145-151. PubMed ID: 28918652
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.
Davies MJ; Gross JL; Ono Y; Sasaki T; Bantwal G; Gall MA; Niemeyer M; Seino H;
Diabetes Obes Metab; 2014 Oct; 16(10):922-30. PubMed ID: 24702700
[TBL] [Abstract][Full Text] [Related]
14. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
Rodbard HW; Cariou B; Pieber TR; Endahl LA; Zacho J; Cooper JG
Diabetes Obes Metab; 2016 Mar; 18(3):274-80. PubMed ID: 26592732
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of fast-acting insulin aspart versus insulin aspart in children and adolescents with type 1 diabetes from Japan.
Kawamura T; Kikuchi T; Horio H; Rathor N; Ekelund M
Endocr J; 2021 Apr; 68(4):409-420. PubMed ID: 33518615
[TBL] [Abstract][Full Text] [Related]
16. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
Bowering K; Case C; Harvey J; Reeves M; Sampson M; Strzinek R; Bretler DM; Bang RB; Bode BW
Diabetes Care; 2017 Jul; 40(7):951-957. PubMed ID: 28483786
[TBL] [Abstract][Full Text] [Related]
17. A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes.
Heise T; Pieber TR; Danne T; Erichsen L; Haahr H
Clin Pharmacokinet; 2017 May; 56(5):551-559. PubMed ID: 28205039
[TBL] [Abstract][Full Text] [Related]
18. Continuous Glucose Monitoring Sensor Glucose Levels and Insulin Pump Infusion Set Wear-Time During Treatment with Fast-Acting Insulin Aspart: A Post Hoc Analysis of Onset 5.
Gorst-Rasmussen A; Sturis J; Ekelund M
Diabetes Technol Ther; 2022 Jan; 24(1):10-17. PubMed ID: 34524005
[No Abstract] [Full Text] [Related]
19. Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart.
Basu A; Pieber TR; Hansen AK; Sach-Friedl S; Erichsen L; Basu R; Haahr H
Diabetes Obes Metab; 2018 Jul; 20(7):1615-1622. PubMed ID: 29493118
[TBL] [Abstract][Full Text] [Related]
20. Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart.
Pieber TR; Svehlikova E; Brunner M; Halberg IB; Due Thomsen KM; Haahr H
Diabetes Obes Metab; 2019 Sep; 21(9):2068-2075. PubMed ID: 31069935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
